In a startling revelation, internal records have surfaced indicating that senior officials from the US Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, last June to discuss legal strategies related to the company’s glyphosate herbicide products. This meeting took place just months before the Trump administration initiated a series of actions that appear to bolster Bayer’s case as it faces significant litigation from consumers alleging that its products, including Roundup, have caused cancer.
Meeting Details and Implications
The gathering on 17 June 2025 included key EPA figures such as agency administrator Lee Zeldin, Nancy Beck, and Sean Donahue, among others. According to planning emails obtained through a Freedom of Information Act request, the agenda specifically included discussions of “supreme court action” and legal updates concerning Bayer’s ongoing litigation struggles. This meeting occurred in a context where Bayer is defending itself against numerous lawsuits claiming that it failed to adequately inform users of the cancer risks associated with its glyphosate-based products.
Bayer’s strategy has been to convince the Supreme Court that, without a mandated cancer warning from the EPA, the company should not be held liable for potential health impacts. While one appellate court has supported Bayer’s stance, various other courts have rejected it, including the Biden administration’s solicitor general.
The Trump Administration’s Support
Following this meeting, the Trump administration’s support for Bayer has been markedly evident. On 1 December 2025, D John Sauer, the solicitor general appointed by Trump, urged the Supreme Court to hear Bayer’s case—a request the court ultimately approved, scheduling a hearing for 27 April. Further, in February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, effectively providing legal immunity for companies like Bayer.
In a subsequent amicus brief filed with the Supreme Court on 2 March, Sauer reiterated the administration’s backing of Bayer’s position. This series of actions has led to accusations that the EPA prioritises corporate interests over public health, particularly regarding chemicals that have been linked to serious health risks.
Reactions from Experts and Advocacy Groups
The implications of this meeting and the subsequent administrative actions have not gone unnoticed by environmental advocacy groups and legal experts. Nathan Donley, director of environmental health science at the Center for Biological Diversity, expressed alarm over the apparent prioritisation of industry interests over the health of American citizens. He stated, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Whitney Di Bona, an attorney and consumer safety advocate, raised further concerns, questioning whether the EPA had offered similar opportunities for dialogue to the thousands of individuals who claim to have developed cancer after using Roundup.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, highlighting a perceived long-standing pattern of corporate influence over regulatory actions. “Coercion by chemical companies on our regulatory agencies is nothing new,” she stated, noting her organisation’s efforts to advocate for pesticide restrictions have yielded little in terms of action from the EPA.
A Pattern of Corporate Influence
The high-level engagement between Bayer’s leadership and the EPA underscores a troubling trend in which corporate interests appear to dictate regulatory outcomes. Naomi Oreskes, a Harvard professor who studies the intersection of corporate influence and regulation, pointed out that such meetings reflect a broader pattern where industry leaders gain access to government officials in ways that the general public does not.
Bayer has defended its actions, asserting that meetings with regulatory bodies are standard practice and that the company has been forthcoming about its position on glyphosate litigation. However, the optics of such high-level discussions raise questions about transparency and the equitable treatment of all stakeholders, particularly those who have suffered adverse health effects.
Why it Matters
The revelations surrounding the EPA’s meeting with Bayer’s CEO and the subsequent actions taken by the Trump administration signal a potential compromise of public health in favour of corporate interests. As the Supreme Court prepares to hear arguments in this pivotal case, the implications extend beyond Bayer and glyphosate; they resonate throughout the regulatory landscape, calling into question the integrity of the decision-making processes that govern public safety. The unfolding scenario serves as a reminder of the critical need for vigilance and accountability in the face of corporate influence over health and environmental regulations.
